{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Janusz CB"],"funding":["NIAID NIH HHS"],"pagination":["4616-4624"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7920528"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(29)"],"pubmed_abstract":["<h4>Background</h4>Although global progress in measles control has been realized, achieving elimination has proven difficult in many regions of the world. China has adopted a goal of measles elimination but recent outbreaks predominantly affecting children <8 months who are ineligible for vaccination and incompletely protected by maternal antibodies has impeded progress. We assess the cost-effectiveness of adding an initial measles vaccine dose in China to earlier than the currently recommended 8 months of age.<h4>Methods</h4>We conducted a cost-utility analysis comparing the costs and health benefits associated with adding a measles vaccine dose to the routine schedule at 4, 5, 6 or 7 months compared to the current recommendation for the first dose at age 8 months. A decision analytic model was developed in Microsoft Excel, including five non-severe and two fatal health outcomes associated with measles infection. Model parameters were informed by the literature and surveillance data. Future costs and health benefits were discounted at 3%. Primary outcomes included costs, Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) over a lifetime time horizon.<h4>Results</h4>Lowering the recommended age for initiating the measles vaccination series to address susceptibility in children <8 months provided incremental health gains compared to minimal costs at the individual-level. The ICER was most favorable ($232.70 per QALY gain) for administering an initial dose at 4 months of age due to fewer incremental program costs when shifting measles administration to an immunization visit already established under the Chinese vaccination program.<h4>Conclusion</h4>We found potential beneficial health gains at a minimum cost associated with adding an earlier measles dose <8 months of age in China. Further investigation about disease transmission dynamics is required to more fully assess the tradeoffs of administering measles at a younger age to infants in China."],"journal":["Vaccine"],"pubmed_title":["Measles vaccination of young infants in China: A cost-effectiveness analysis."],"pmcid":["PMC7920528"],"funding_grant_id":["U01 AI088671"],"pubmed_authors":["Masters NB","Janusz CB","Wagner AL","Ding Y","Zhang Y","Boulton ML","Hutton DW"],"additional_accession":[]},"is_claimable":false,"name":"Measles vaccination of young infants in China: A cost-effectiveness analysis.","description":"<h4>Background</h4>Although global progress in measles control has been realized, achieving elimination has proven difficult in many regions of the world. China has adopted a goal of measles elimination but recent outbreaks predominantly affecting children <8 months who are ineligible for vaccination and incompletely protected by maternal antibodies has impeded progress. We assess the cost-effectiveness of adding an initial measles vaccine dose in China to earlier than the currently recommended 8 months of age.<h4>Methods</h4>We conducted a cost-utility analysis comparing the costs and health benefits associated with adding a measles vaccine dose to the routine schedule at 4, 5, 6 or 7 months compared to the current recommendation for the first dose at age 8 months. A decision analytic model was developed in Microsoft Excel, including five non-severe and two fatal health outcomes associated with measles infection. Model parameters were informed by the literature and surveillance data. Future costs and health benefits were discounted at 3%. Primary outcomes included costs, Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) over a lifetime time horizon.<h4>Results</h4>Lowering the recommended age for initiating the measles vaccination series to address susceptibility in children <8 months provided incremental health gains compared to minimal costs at the individual-level. The ICER was most favorable ($232.70 per QALY gain) for administering an initial dose at 4 months of age due to fewer incremental program costs when shifting measles administration to an immunization visit already established under the Chinese vaccination program.<h4>Conclusion</h4>We found potential beneficial health gains at a minimum cost associated with adding an earlier measles dose <8 months of age in China. Further investigation about disease transmission dynamics is required to more fully assess the tradeoffs of administering measles at a younger age to infants in China.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2024-02-15T02:40:36.654Z","creation":"2022-02-10T14:37:31.052Z"},"accession":"S-EPMC7920528","cross_references":{"pubmed":["32451210"],"doi":["10.1016/j.vaccine.2020.04.079"]}}